Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C-MER Medical HoldingsHKSE:03309 -0.58%83 EV-to-FCF is 5.65 as of Aug. 29, 2026, which is 61% below its 10-year median of 14.65. GuruFocus rates HKSE:03309 with a GF Score™ of 83/100 and a GF Value™ of HK$2.77 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 415 Healthcare Providers & Services companies, C-MER Medical Holdings ranks better than 87.47% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, C-MER Medical Holdings's Enterprise Value is HK$1,143 Mil.
C-MER Medical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$202 Mil. Therefore, C-MER Medical Holdings's EV-to-FCF for today is 5.65.
The historical rank and industry rank for C-MER Medical Holdings's EV-to-FCF or its related term are showing as below:
HKSE:03309'
s EV-to-FCF Range Over the Past 10 Years
Min: -10492.15 Med: 14.65 Max: 712
Current: 5.53
During the past 12 years, the highest EV-to-FCF of C-MER Medical Holdings was 712.00. The lowest was -10492.15. And the median was 14.65.
HKSE:03309's EV-to-FCF is ranked better than 87.47% of 415
companies
in the Healthcare Providers & Services industry
Industry Median: 18.31
vs HKSE:03309: 5.53
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
C-MER Medical Holdings (HKSE:03309) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
C-MER Medical Holdings's PE Ratio (TTM) for today is calculated as:
C-MER Medical Holdings's share price for today is HK$0.855.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. C-MER Medical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.083.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, C-MER Medical Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-MER Medical Holdings EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, C-MER Medical Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where C-MER Medical Holdings's EV-to-FCF falls into.
C-MER Medical Holdings's current Enterprise Value is HK$1,143 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. C-MER Medical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$202 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-MER Medical Holdings (HKSE:03309) has a EV-to-FCF of 5.65 as of Aug. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on C-MER Medical Holdings and its competitors. This is 61% below median its historical median of 14.65. According to the industry distribution chart, C-MER Medical Holdings ranks #52 out of 415 companies in the Healthcare Providers & Services industry, placing it in the top 12.5%.
Is C-MER Medical Holdings' EV-to-FCF too high?
C-MER Medical Holdings' current EV-to-FCF of 5.65 is 61% below median its 10-year median of 14.65. The Healthcare Providers & Services industry median EV-to-FCF is 18.31. C-MER Medical Holdings' value of 5.65 is 69.1% below this industry median. Based on the distribution chart, C-MER Medical Holdings ranks #52 out of 415 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, C-MER Medical Holdings has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does C-MER Medical Holdings' EV-to-FCF compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, C-MER Medical Holdings ranks #52 out of 415 companies for EV-to-FCF. This places C-MER Medical Holdings in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 18.31. C-MER Medical Holdings' value of 5.65 is 69.1% below this benchmark. While the company's 10-year median is 14.65 vs. the industry median of 18.31, C-MER Medical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.31, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-MER Medical Holdings's current EV-to-FCF of 5.65 is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on C-MER Medical Holdings and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-MER Medical Holdings's current EV-to-FCF is 5.65, which is 61% below median its own 10-year median of 14.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-MER Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, C-MER Medical Holdings (HKSE:03309) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.77, compared to a current price of HK$0.86 — trading 69.1% below its estimated fair value. The current EV-to-FCF is 5.65, which is 61% below median its 10-year median of 14.65 and 69.1% below the Healthcare Providers & Services industry median of 18.31. C-MER Medical Holdings' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For C-MER Medical Holdings (HKSE:03309), the current EV-to-FCF is 5.65 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-MER Medical Holdings (HKSE:03309) Overvalued in 2026?
Based on GuruFocus' analysis, C-MER Medical Holdings stock appears to be undervalued.
The current stock price of HK$0.86 is trading 69.1% below its estimated GF Value™ of HK$2.77.
GuruFocus considers C-MER Medical Holdings to be Possible Value Trap.
Key valuation signals for HKSE:03309:
EV-to-FCF: 5.65 (61% below median its 10-year median of 14.65)
GF Value™: HK$2.77 vs. price of HK$0.86 (69.1% below fair value)
Industry Position: 69.1% below the Healthcare Providers & Services median (#52 of 415)
No single metric tells the full story. See the HKSE:03309 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-MER Medical Holdings Ltd is a ophthalmic medical chain group in Hong Kong and the Greater Bay Area. With ophthalmology as its core, it has gradually expanded its business scope to different specialist services. The company through its subsidiaries are principally engaged in the provision of ophthalmic, dental and other medical services, sales of vision aid products and sales of medical consumables in Hong Kong and Mainland China. Geographically, the company generates revenue from Mailand China, and Hong Kong, with the majority of revenue generated from Mainland China.
83GF Score
Get the complete analysis for HKSE:03309
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03309 has been successfully added to your 
